Evidence map›Paper›PMID 23452076›Full record

ArticleAllergy2013

Attenuated allergic airway inflammation in Cd39 null mice.

M Idzko, C K Ayata, T Müller, T Dürk, M Grimm, K Baudiß, R P Vieira, S Cicko, C Boehlke, A Zech and 4 more

Open access · greenAbstract read
In one paragraph

Article in Allergy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.4field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Adenosine Signaling in Mast Cells and Allergic Diseases.International journal of molecular sciences · 2021
    Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. What Else Can CD39 Tell Us?Frontiers in immunology · 2017
    Review
  11. Article
  12. Article
  13. Purinergic signalling and immune cells.Purinergic signalling · 2014
    Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 3 countries.

M IdzkoDepartment of Pneumology, University Medical Center, Freiburg, Germany. marco.idzko@uniklinik-freiburg.de
C K Ayata
T Müller
T Dürk
M Grimm
K Baudiß
R P Vieira
S Cicko
C Boehlke
A Zech
S Sorichter
J Pelletier
J Sévigny
S C Robson
University Medical Center · USBeth Israel Deaconess Medical Center · USCentre hospitalier universitaire de Québec · CAUniversité Laval · CAUniversity Medical Center Freiburg · DE

Funding

Thrombus Formation In VivoP01HL087203 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI FURIE, BRUCE · 2008 to 2012
$8.8M
Purinergic ThromboregulationR01HL094400 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI ROBSON, SIMON C. · 2009 to 2010
$1.4M
Engineering Inhibitory Antibodies to Ectoenzymes for Cancer TreatmentR21CA164970 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI ROBSON, SIMON C. · 2012 to 2013
$405k
NCI NIH HHS R21 CA164970NHLBI NIH HHS P01 HL087203NHLBI NIH HHS R01 HL094400
6 · The paper itself

Abstract

backgroundExtracellular Adenosine-5'-Triphosphate (ATP) is known to accumulate in the lung, following allergen challenge, and contributes via activation of purinergic receptors on dendritic cells (DC), to the development of allergic airway inflammation (AAI). Extracellular ATP levels in the airways are normally tightly regulated by CD39. This ectonucleotidase is highly expressed by DC purified from skin (Langerhans cells) and bone marrow, and has been shown to modulate DC adaptive/haptenic immune responses. In this study, we have evaluated the impact of Cd39 deletion and associated perturbation of purinergic signaling in AAI.

methodsStandard ovalbumin (OVA)-alum and house dust mite (HDM) bone marrow-derived DC (BMDC)-dependent models of AAI were used to study effects of Cd39. Migration assays, time lapse microscopy, and T-cell priming assays were further used to determine functional relevance of Cd39 expression on BMDC in the setting of immune and Th2-mediated responses in these models.

resultsCd39(-/-) mice exhibited marked increases in BALF ATP levels but paradoxically exhibited limited AAI in both OVA-alum and HDM models. These pathophysiological abnormalities were associated with decreased myeloid DC activation and chemotaxis toward ATP, and were linked to purinergic receptor desensitization responses. Further, Cd39(-/-) DCs exhibited limited capacity to both prime Th2 responses and form stable immune synaptic interactions with OVA-transgenic naïve T cells.

conclusionsCd39-deficient DCs exhibit limited capacity to induce Th2 immunity in a DC-driven model of AAI in vivo. Our data demonstrate a role of CD39 and perturbed purinergic signaling in models of AAI.

Indexed as

Adenosine TriphosphateAlum CompoundsAnimalsAntigens, CDApyraseAsthmaCell MovementCytokinesDendritic CellsDisease Models, AnimalFemaleGene Expression RegulationLungMiceMice, KnockoutOvalbuminAdenosine TriphosphateAlum CompoundsAntigens, CDApyraseCD39 antigenCytokinesOvalbuminovalbumin-alum

Identifiers

PMID23452076
PMCPMC5291121
OpenAlexW2003262834

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.